Drugs & Therapy Perspectives

, Volume 20, Issue 6, pp 1–4 | Cite as

Tegaserod: a promising option in women with irritable bowel syndrome with constipation

Drugs and Profile Report


Irritable Bowel Syndrome Tegaserod Receptor Partial Agonist Osmotic Laxative Irritable Bowel Syndrome With Constipation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Forbes A. IBS: guide to diagnosis and recommended treatment. Prescriber 1997 Apr 19; 8: 67–72Google Scholar
  2. 2.
    Wagstaff AJ, Frampton JE, Croom KF. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs 2003; 63(11): 1101–20PubMedCrossRefGoogle Scholar
  3. 3.
    Fass R, Longstreth GF, Pimental M, et al. Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch Intern Med 2001 Sep 24; 161(17): 2081–8PubMedCrossRefGoogle Scholar
  4. 4.
    Dunphy RC, Verne GN. Drug treatment options for irritable bowel syndrome: managing for success. Drugs Aging 2001; 18(3): 201–11PubMedCrossRefGoogle Scholar
  5. 5.
    American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 2002; 123: 2105-7Google Scholar
  6. 6.
    Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999 Nov 8; 107(5A): 91S–7SPubMedCrossRefGoogle Scholar
  7. 7.
    Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care 2001 Jul; 7(8 Suppl. ): S252–60PubMedGoogle Scholar
  8. 8.
    Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671–6PubMedCrossRefGoogle Scholar
  9. 9.
    Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome in patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 Oct; 15(10): 1655–66PubMedCrossRefGoogle Scholar
  10. 10.
    Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002 Nov; 16(11): 1877–88PubMedCrossRefGoogle Scholar
  11. 11.
    Bardhan KD, Forbes A, Marsden CL. A clinical investigation of the effects of tegaserod treatment regimen on the symptoms of IBS-C in tegaserod responsive patients [abstract no. 053]. Gut 2003; 52 Suppl. 1: A14–5Google Scholar
  12. 12.
    Tougas G, Snape Jr WJ, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002 Oct; 16(10): 1701–8PubMedCrossRefGoogle Scholar
  13. 13.
    Whorwell PJ, Krumholz S, Mueller Lissner S, et al. Tegaserod has a favorable safety & tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome (IBS) [abstract no. 5529]. Gastroenterology 2000 Apr; 118 Suppl. 2, Pt 2: A1204CrossRefGoogle Scholar
  14. 14.
    Earnest D, Rueegg PC, Dunger Baldauf C, et al. Diarrhea in patients treated with tegaserod for irritable bowel syndrome with constipation (IBS-C) is infrequent and usually self-limited [abstract no. 843]. Am J Gastroenterol 2002 Sep; 97 Suppl. : S277CrossRefGoogle Scholar
  15. 15.
    Plebani G, Fried M, Michetti P, et al. Safety of tegaserod in patients with irritable bowel syndrome: the Swiss experience [abstract no. WED-G-323]. Gut 2002; 51 Suppl. III: A249Google Scholar
  16. 16.
    Fidelholtz J, Smith W, Rawls J, et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol 2002 May; 97(5): 1176–81PubMedCrossRefGoogle Scholar
  17. 17.
    Poole RM. Tegaserod relieves global symptoms of irritable bowel syndrome. Inpharma 2002 Aug 10; 1350: 13–4Google Scholar
  18. 18.
    Novartis. Integrated summary of safety — update. 2002Google Scholar
  19. 19.
    Ruegg P, Lefkowitz M, Drossman D, et al. Tegaserod alone or in combination with antidepressant drugs is well tolerated in patients with IBS-C [abstract no. 851]. Am J Gastroenterol 2002 Sep; 97 Suppl. : S279–80CrossRefGoogle Scholar
  20. 20.
    Novartis Pharmaceuticals Corporation. Zelnorm (tegaserod maleate) tablets: prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2002Google Scholar
  21. 21.
    Novartis Pharmaceuticals Canada Inc. Prescribing information: Zelnorm (tegaserod hydrogen maleate) tablets. Dorval (QC): Novartis Pharmaceuticals Canada Inc., 2002Google Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations